Drug Approval | October 14, 2021
IOL receives Korean FDA approval
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
The company plans to expand its portfolio in regulated markets aggressively
The new devices company will scale up its teams to create a world-class R&D centre for medical devices in India
CuraTeQ Biologics is on track for filing a second oncology biosimilar
In H1FY21, it attracted PE deals worth US $ 1.6 billion compared to US $ 3 billion in CY2020
The acquisition was expected to be completed in eight weeks, and it would have provided it with a foothold in the US $ 48 billion global animal health market
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
The company has tied up with OrbiMed as a financial partner for global reach
Formulation business grew by 15 per cent in the quarter
The company expects revenue growth of 10-15 per cent in the US
Subscribe To Our Newsletter & Stay Updated
